Design, Synthesis, and Biological Evaluation of Novel C5-Modified Pyrimidine Ribofuranonucleosides as Potential Antitumor or/and Antiviral Agents
作者:Nikolaos Kollatos、Christos Mitsos、Stella Manta、Niki Tzioumaki、Christos Giannakas、Tania Alexouli、Aggeliki Panagiotopoulou、Dominique Schols、Graciela Andrei、Dimitri Komiotis
DOI:10.2174/1573406415666190225112950
日期:2020.4.17
BACKGROUND Nucleoside analogues are well-known antitumor, antiviral, and chemotherapeutic agents. Alterations on both their sugar and the heterocyclic parts may lead to significant changes in the spectrum of their biological activity and the degree of selective toxicity, as well as in their physicochemical properties. METHODS C5-arylalkynyl-β-D-ribofuranonucleosides 3-6, 3΄-deoxy 12-15, 3΄-deoxy-3΄-C-methyl-
背景技术核苷类似物是众所周知的抗肿瘤剂,抗病毒剂和化学治疗剂。它们的糖和杂环部分的改变都可能导致其生物学活性和选择性毒性程度以及其理化性质发生重大变化。方法C5-芳基炔基-β-D-呋喃核苷3-6、3′-脱氧12-15、3′-脱氧-3′-C-甲基-β-D-呋喃呋喃核苷18-21和2′-脱氧-β-尿嘧啶的D-呋喃核糖核苷23-26,是在微波辐射下通过一步Sonogashira反应合成的,然后进行脱保护。结果测试了所有新合成的核苷的抗肿瘤或抗病毒活性。针对宫颈癌(HeLa)的中等细胞抑制活性,受保护的3′-脱氧衍生物12b,12c,12d和3′-脱氧-3′-甲基18a,18b,18c显示出鼠白血病(L1210)和人淋巴细胞(CEM)肿瘤细胞系。抗病毒评估显示,该化合物对3 Co-脱氧化合物12b,14和3΄-脱氧-3΄-甲基18a,18c具有明显的抗柯萨奇病毒B4,呼吸道合胞病毒,黄热病毒和人冠状病毒(229E)的活性,